Man-Fung Yuen, Scott Fung, Xiaoli Ma, Tuan T Nguyen, Tarek Hassanein, Hie-Won Hann, Magdy Elkhashab, Ronald G Nahass, James S Park, Ira M Jacobson, Walid S Ayoub, Steven-Huy Han, Edward J Gane, Katie Zomorodi, Ran Yan, Julie Ma, Steven J Knox, Luisa M Stamm, Maurizio Bonacini, Frank Weilert, Alnoor Ramji, Michael Bennett, Natarajan Ravendhran, Sing Chan, Douglas T Dieterich, Paul Yien Kwo, Eugene R Schiff, Ho S Bae, Jacob Lalezari, Kosh Agarwal, Mark S Sulkowski
BACKGROUND & AIMS: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In this long-term extension study, patients received open-label VBR with nucleos(t)ide reverse transcriptase inhibitors (NrtIs). METHODS: Patients in this study (NCT03780543) previously received VBR + NrtI or placebo + NrtI in parent studies 201 (NCT03576066) or 202 (NCT03577171)...
April 2024: JHEP reports: innovation in hepatology